Mesothelioma Clinical Trials that are Recruiting
Individuals diagnosed with mesothelioma may find new treatment opportunities and contribute to medical advancement by participating in clinical trials. These medical research studies are essential in developing and testing new therapies and involve numerous active trials seeking eligible mesothelioma patients.
Purpose and Impact of Mesothelioma Clinical Studies
Clinical trials are instrumental in evaluating the safety and effectiveness of novel mesothelioma treatments. Successful outcomes in these trials can lead to regulatory approval, as seen with the immunotherapy combination of Opdivo® and Yervoy®. This treatment showed promise in clinical studies, notably extending the survival of patients, and subsequently received FDA approval for treating inoperable pleural mesothelioma.
Treatments from Mesothelioma Clinical Trials
Current mesothelioma clinical trials explore a range of emerging treatments, including:
- Cancer Vaccines: This form of immunotherapy trains the immune system to target and attack cancer cells.
- Cryotherapy: A technique using extreme cold to destroy cancerous tissues.
- Immunotherapy: Treatments that harness the body’s immune system to fight cancer.
- Multimodal Therapy: Combining multiple therapies, such as surgery, chemotherapy, and radiation.
- Photodynamic Therapy: Using light-sensitive drugs and light exposure to kill cancer cells.
- Radical Surgery: Aggressive surgical methods aimed at removing extensive mesothelioma tumors.
These trials often begin with laboratory research and animal studies before advancing to human trials.
Clinical Trial Recommendations for Mesothelioma Patients
Mesothelioma patients, particularly those with limited treatment options, might access groundbreaking therapies through clinical trials. The American Society of Clinical Oncology (ASCO) advises clinical trial participation for patients in specific situations, such as those eligible for second-line chemotherapy, those with tumor spread to lymph nodes, or candidates for radiation therapy either before or after surgery.
Benefits and Risks of Clinical Trials
Participation in clinical trials is an important decision that involves weighing potential benefits against risks. Patients are encouraged to engage in detailed discussions with their healthcare team to understand the implications of enrolling in a clinical trial.
Clinical Trials Currently Recruiting for Patients with Mesothelioma
- Integrated Cancer Repository for Cancer Research (iCaRe2)
- Conditions: Various cancers including Multiple Myeloma, Pancreatic Neoplasms, Esophageal Neoplasms, and more
- Last Updated: August 9, 2023
- Status: Recruiting
- Locations: Multiple locations in Colorado, Florida, Illinois, Indiana, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, New York, North Carolina, North Dakota, Pennsylvania, South Dakota, Vermont, Virginia, Wisconsin.
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
- Conditions: Various rare tumors including Carcinoma, Neoplasms, and more
- Last Updated: August 1, 2023
- Status: Recruiting
- Locations: Multiple locations in Alabama, Alaska, Florida.
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
- Conditions: Various solid tumors including Carcinoma, Small Cell Lung Carcinoma, Endometrial Neoplasms, and more
- Last Updated: July 3, 2023
- Status: Recruiting
- Locations: Multiple locations in California, Florida, Massachusetts, New Jersey.
- DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R)
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: June 28, 2023
- Status: Recruiting
- Locations: Multiple locations in California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York, Ohio, Pennsylvania, Tennessee, Texas.
- Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment for Stage I-IIIA Malignant Pleural Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms
- Last Updated: March 28, 2023
- Status: Recruiting
- Locations: Multiple locations in Florida, Illinois, Massachusetts, Minnesota, New Jersey, New York, Ohio, Texas, Washington.
- Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
- Conditions: Carcinoma, Melanoma, Mesothelioma, Oropharynx Cancer, and more
- Last Updated: March 10, 2023
- Status: Recruiting
- Locations: Multiple locations in Arizona, Florida, Kansas, Massachusetts, Minnesota, Montana, Texas.
- A Study of SGN-CD228A in Advanced Solid Tumors
- Conditions: Mesothelioma
- Last Updated: November 1, 2022
- Status: Recruiting
- Locations: Multiple locations in Alabama, California, Illinois, North Carolina, Ohio, Oregon, Pennsylvania, South Dakota, Texas, Virginia.
- Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: November 1, 2022
- Status: Recruiting
- Locations: Philadelphia, PA.
- Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
- Conditions: Mesothelioma, Mesothelioma, Malignant, Gastrointestinal Neoplasms, and more
- Last Updated: October 31, 2022
- Status: Recruiting
- Locations: Bethesda, Maryland.
- Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
- Conditions: Esophageal Neoplasms, Mesothelioma, Mesothelioma, Malignant, Neoplasms
- Last Updated: October 27, 2022
- Status: Recruiting
- Locations: Bethesda, Maryland.
- Rapid Autopsy and Procurement of Cancer Tissue
- Conditions: Mesothelioma, Urogenital Neoplasms
- Last Updated: October 26, 2022
- Status: Recruiting
- Locations: Bethesda, Maryland.
- Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms
- Last Updated: October 25, 2022
- Status: Recruiting
- Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
- Conditions: Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant, Esophageal Neoplasms
- Last Updated: October 25, 2022
- Status: Recruiting
- Location: Bethesda, MD.
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
- Conditions: Various cancers including Carcinoma, Merkel Cell, Carcinoma, Neoplasms, and more
- Last Updated: October 24, 2022
- Status: Recruiting
- Locations: Boston, MA. Detroit, MI. Pittsburgh, PA. Houston, TX. Seattle, WA.
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
- Conditions: Various cancers including Carcinoma, Merkel Cell, Carcinoma, Neoplasms, and more
- Last Updated: October 21, 2022
- Status: Recruiting
- Locations: Hackensack, NJ. Greenville, SC. Nashville, TN.
- The Registry of Oncology Outcomes Associated With Testing and Treatment
- Conditions: Various cancers including Sarcoma, Kaposi, Carcinoma, Neoplasms, Leukemia, and more
- Last Updated: October 19, 2022
- Status: Recruiting
- Location: Idaho Falls, ID.
- A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: October 18, 2022
- Status: Recruiting
- Locations: Chicago, Illinois. Boston, Massachusetts. Houston, Texas.
- Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
- Conditions: Various cancers including Carcinoma, Lung Neoplasms, Mesothelioma, and more
- Last Updated: October 17, 2022
- Status: Recruiting
- Location: Columbus, GA.
- Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance
- Conditions: Various cancers including Carcinoma, Melanoma, Mesothelioma
- Last Updated: October 17, 2022
- Status: Recruiting
- Location: Oakland, California.
- A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
- Conditions: Mesothelioma
- Last Updated: October 13, 2022
- Status: Recruiting
- Locations: Los Angeles, California. San Diego, California. Santa Monica, California. Tampa, Florida. Covington, Louisiana. New York, New York. Durham, North Carolina. Cincinnati, Ohio. Cleveland, Ohio. Columbus, Ohio. Pittsburgh, Pennsylvania. Nashville, Tennessee. Houston, Texas. Fredericksburg, Virginia. Lynchburg, Virginia. Madison, Wisconsin.
- A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: October 10, 2022
- Status: Recruiting
- Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
- Conditions: Various cancers including Pancreatic Cancer, Cholangiocarcinoma, Mesothelioma, and more
- Last Updated: October 10, 2022
- Status: Recruiting
- Locations: New Haven, Connecticut. Detroit, Michigan. New York, New York. Houston, Texas.
- Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
- Conditions: Mesothelioma
- Last Updated: October 10, 2022
- Status: Recruiting
- Locations: Gilbert, Arizona. Los Angeles, California. Sarasota, Florida. Grand Rapids, Michigan. Austin, Texas. Houston, Texas.
- A Study of HFB200301 in Adult Patients With Advanced Solid Tumors
- Conditions: Various cancers including Mesothelioma, Gastric Cancer, Melanoma, and more
- Last Updated: October 7, 2022
- Status: Recruiting
- Locations: Scottsdale, Arizona. Los Angeles, California. Jacksonville, Florida. Rochester, Minnesota. Saint Louis, Missouri. Houston, Texas. Fairfax, Virginia.
- A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
- Conditions: Various cancers including Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse, Mesothelioma, and more
- Last Updated: October 6, 2022
- Status: Recruiting
- Locations: Atlanta, GA. Chicago, IL. Baltimore, MD. Boston, MA. Ann Arbor, MI. Grand Rapids, MI. Hackensack, NJ. Bronx, NY. New York, NY. Cincinnati, OH. San Antonio, TX. Charlottesville, VA. Seattle, WA.
- Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: October 5, 2022
- Status: Recruiting
- Location: Bethesda, Maryland.
- Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
- Conditions: Mesothelioma, Mesothelioma, Malignant, Syndrome, Disease Susceptibility
- Last Updated: October 5, 2022
- Status: Recruiting
- Location: Bethesda, MD.
- Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
- Conditions: Neoplasms
- Last Updated: October 5, 2022
- Status: Recruiting
- Locations: Duarte, CA. Los Angeles, CA. Newport Beach, CA. Iowa City, IA. Ann Arbor, MI. New York, NY. Philadelphia, PA. Houston, TX. San Antonio, TX. Fairfax, VA.
- Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
- Conditions: Neoplasms, Mesothelioma, Mesothelioma, Malignant, Pancreatic Neoplasms, Stomach Neoplasms, Thymoma, Biliary Tract Neoplasms
- Last Updated: October 5, 2022
- Status: Recruiting
- Location: Bethesda, Maryland.
- Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Conditions: Any Solid Tumors, Mesothelioma, Head and Neck Squamous Cell Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Lung, Esophageal Cancer, Adenoid Cystic Carcinoma, Prostate Cancer, Cervical Cancer, Melanoma
- Last Updated: September 30, 2022
- Status: Recruiting
- Locations: Duarte, California. New York, New York. Houston, Texas. Milwaukee, Wisconsin. Canton, Ohio.
- Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant, Neoplasms, Fibrous Tissue, Solitary Fibrous Tumors, Pleural Neoplasms, Solitary Fibrous Tumor, Pleural, Hemangiopericytoma
- Last Updated: September 28, 2022
- Status: Recruiting
- Location: Rochester, MN.
- Staging Procedures to Diagnose Malignant Pleural Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant, Neoplasms, Fibrous Tissue, Solitary Fibrous Tumors, Pleural Neoplasms, Solitary Fibrous Tumor, Pleural
- Last Updated: September 28, 2022
- Status: Recruiting
- Location: Rochester, MN.
- Stereotactic Magnetic Resonance Guided Radiation Therapy
- Conditions: Prostatic Neoplasms, Neoplasm Metastasis, Neoplasms, Second Primary, Brain Neoplasms, Mesothelioma, Pancreatic Neoplasms, Kidney Neoplasms, Carcinoma, Renal Cell
- Last Updated: September 27, 2022
- Status: Recruiting
- Locations: Boston, MA. Boston, MA.
- Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
- Conditions: Neoplasms, Melanoma, Mesothelioma, Mesothelioma, Malignant, Skin Neoplasms, Lung Neoplasms, Bone Neoplasms, Genital Neoplasms, Female, Soft Tissue Neoplasms, Pharyngeal Neoplasms, Endocrine Gland Neoplasms, Mouth Neoplasms, Urologic Neoplasms, Thyroid Neoplasms, Genital Neoplasms, Male, Sarcoma, Thyroid Diseases, Recurrence
- Last Updated: September 26, 2022
- Status: Recruiting
- Location: Houston, TX.
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
- Conditions: Carcinoma, Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Stomach Neoplasms, Uterine Cervical Neoplasms, Mesothelioma, Mesothelioma, Malignant, Carcinoma, Transitional Cell, Endometrial Neoplasms, Bile Duct Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Penile Neoplasms
- Last Updated: September 26, 2022
- Status: Recruiting
- Locations: Sacramento, CA. Bethesda, MD. Bethesda, MD. Columbus, OH. Pittsburgh, PA. Madison, WI. New York, NY.
- A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
- Conditions: Neoplasms, Adenocarcinoma, Mesothelioma, Cystadenocarcinoma, Serous
- Last Updated: September 22, 2022
- Status: Recruiting
- Locations: Bethesda, Maryland. Nashville, Tennessee.
- Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions: Carcinoma, Glioblastoma, Mesothelioma, Cholangiocarcinoma, Squamous Cell Carcinoma of Head and Neck
- Last Updated: September 15, 2022
- Status: Recruiting
- Locations: Los Angeles, California. Newport Beach, California. Santa Monica, California. Sarasota, Florida. Baltimore, Maryland. Boston, Massachusetts. Grand Rapids, Michigan. Omaha, Nebraska. Greenville, South Carolina. Houston, Texas. San Antonio, Texas.
- A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
- Conditions: Mesothelioma
- Last Updated: September 15, 2022
- Status: Recruiting
- Locations: Houston, Texas.
- Dose Individualization of Pemetrexed – IMPROVE-I
- Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant
- Last Updated: September 10, 2022
- Status: Recruiting
- Surgery for Mesothelioma After Radiation Therapy “SMART” for Resectable Malignant Pleural Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant, Neoplasms, Fibrous Tissue, Solitary Fibrous Tumors, Pleural Neoplasms, Solitary Fibrous Tumor, Pleural
- Last Updated: September 8, 2022
- Status: Recruiting
- Location: Rochester, MN.
- Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
- Conditions: Carcinoma, Melanoma, Mesothelioma
- Last Updated: September 1, 2022
- Status: Recruiting
- Locations: Boston, Massachusetts.
- A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: August 26, 2022
- Status: Recruiting
- Locations: Basking Ridge, New Jersey. Middletown, New Jersey. Montvale, New Jersey. Commack, New Jersey. Harrison, New Jersey. New York, New York. Rockville Centre, New York.
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
- Conditions: Mesothelioma
- Last Updated: August 25, 2022
- Status: Recruiting
- Locations: Phoenix, AZ. Chicago, IL. Danville, IL. Effingham, IL. Matoon, IL. Urbana, IL. Lexington, KY. Boston, MA. Bemidji, MN. Edina, MN. Minneapolis, MN. Rochester, MN. Bismarck, ND. Fargo, ND. Columbus, OH. Oklahoma City, OK. Pittsburgh, PA. Sioux Falls, SD.
- Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
- Conditions: Mesothelioma, Locally Advanced Solid Tumor
- Last Updated: August 22, 2022
- Status: Recruiting
- Locations: Boston, Massachusetts. Boston, Massachusetts. Nashville, Tennessee. Houston, Texas. San Antonio, Texas. Fairfax, Virginia.
- APG-2449 in Patients With Advanced Solid Tumors
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: August 19, 2022
- Status: Recruiting
- A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
- Conditions: Mesothelioma
- Last Updated: August 17, 2022
- Status: Recruiting
- Locations: Boca Raton, Florida. Orlando, Florida. Atlanta, Georgia.
- Oral AMXT 1501 Dicaprate in Combination With IV DFMO
- Conditions: Endometrial Neoplasms, Mesothelioma, Diffuse Intrinsic Pontine Glioma
- Last Updated: August 15, 2022
- Status: Recruiting
- Location: Houston, Texas.
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Conditions: Adenocarcinoma, Sarcoma, Mesothelioma, Mesothelioma, Malignant, Sarcoma, Ewing, Chondrosarcoma
- Last Updated: August 12, 2022
- Status: Recruiting
- Locations: Scottsdale, AZ. Duarte, CA. Los Angeles, CA. Santa Monica, CA. Aurora, CO. Atlanta, GA. Chicago, IL. Ann Arbor, MI. Grand Rapids, MI. New York, NY. Cleveland, OH. Philadelphia, PA. Houston, TX. San Antonio, TX.
- KZR-261 in Subjects With Advanced Solid Malignancies
- Conditions: Mesothelioma, Neoplasms
- Last Updated: August 12, 2022
- Status: Recruiting
- Locations: Los Angeles, California. Tampa, Florida. Atlanta, Georgia. Philadelphia, Pennsylvania. Nashville, Tennessee. San Antonio, Texas. Fairfax, Virginia.
- Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Conditions: Mesothelioma, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma, Solid Tumor
- Last Updated: August 10, 2022
- Status: Recruiting
- Locations: Denver, Colorado. Boston, Massachusetts. New York, New York. Nashville, Tennessee. Houston, Texas. San Antonio, Texas.
- A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
- Conditions: Mesothelioma
- Last Updated: August 5, 2022
- Status: Recruiting
- Locations: Duarte, California. La Jolla, California. Aurora, Colorado. Denver, Colorado. Boston, Massachusetts. Philadelphia, Pennsylvania. San Antonio, Texas.
- A Study of NX-1607 in Adults With Advanced Malignancies
- Conditions: Carcinoma, Neoplasms, Triple Negative Breast Neoplasms, Mesothelioma, Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer, Carcinoma, Ovarian Epithelial
- Last Updated: July 27, 2022
- Status: Recruiting
- Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: July 26, 2022
- Status: Recruiting
- Locations: Buffalo, NY. Philadelphia, PA.
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
- Conditions: Carcinoma, Merkel Cell, Mesothelioma, Neuroendocrine Tumors, Neoplasms, Squamous Cell, Carcinoma, Squamous Cell, Microsatellite Instability
- Last Updated: July 22, 2022
- Status: Recruiting
- Location: Pittsburgh, PA.
- Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: July 22, 2022
- Status: Recruiting
- Locations: Baltimore, MD. Baltimore, MD. Houston, TX.
- Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
- Conditions: Neoplasms
- Last Updated: July 22, 2022
- Status: Recruiting
- Locations: Scottsdale, Arizona. Duarte, California. Indianapolis, Indiana. Baltimore, Maryland. Boston, Massachusetts. New York, New York. New York, New York. Oklahoma City, Oklahoma. Nashville, Tennessee. Houston, Texas. San Antonio, Texas.
- Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- Conditions: Carcinoma, Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma, Meningioma, Disease Susceptibility
- Last Updated: July 11, 2022
- Status: Recruiting
- Location: Columbus, Ohio.
- Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
- Conditions: Neoplasms, Neoplasm Metastasis
- Last Updated: July 11, 2022
- Status: Recruiting
- Locations: Grand Rapids, Michigan. Houston, Texas. San Antonio, Texas.
- Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
- Conditions: Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms, Pleural Diseases
- Last Updated: June 21, 2022
- Status: Recruiting
- Location: Buffalo, NY.
- A Study of Pembrolizumab and Cryoablation in People With Mesothelioma
- Conditions: Mesothelioma
- Last Updated: June 16, 2022
- Status: Recruiting
- Locations: Basking Ridge, New Jersey. Middletown, New Jersey. Montvale, New Jersey. Commack, New York. Harrison, New York. New York, New York. Uniondale, New York.
- Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
- Conditions: Mesothelioma
- Last Updated: June 7, 2022
- Status: Recruiting
- Locations: Boston, Massachusetts. Grand Rapids, Michigan. Philadelphia, Pennsylvania. Nashville, Tennessee. Houston, Texas. San Antonio, Texas.
- Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: June 2, 2022
- Status: Recruiting
- Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
- Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant, Cholangiocarcinoma
- Last Updated: May 27, 2022
- Status: Recruiting
- Locations: San Francisco, CA. Bethesda, MD. New York, NY. Philadelphia, PA. Nashville, TN. Houston, TX.
- A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
- Conditions: Neoplasm Metastasis, Melanoma, Primary Myelofibrosis
- Last Updated: May 20, 2022
- Status: Recruiting
- Surgery for Mesothelioma After Radiation Therapy Using Exquisite Systemic Therapy
- Conditions: Mesothelioma
- Last Updated: May 19, 2022
- Status: Recruiting
- Location: Toronto, California.
- Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: May 18, 2022
- Status: Recruiting
- Location: Chicago, IL.
- Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study
- Conditions: Carcinoma, Neoplasms, Sarcoma, Mesothelioma
- Last Updated: May 11, 2022
- Status: Recruiting
- Location: Rochester, MN.
- Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
- Conditions: Mesothelioma
- Last Updated: May 3, 2022
- Status: Recruiting
- Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: April 15, 2022
- Status: Recruiting
- Mesothelioma Stratified Therapy (MiST): A Multi-drug Phase II Trial in Malignant Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: April 7, 2022
- Status: Recruiting
- Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: April 4, 2022
- Status: Recruiting
- Location: New York, New York.
- Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: March 23, 2022
- Status: Recruiting
- Location: Boston, MA.
- CAR T Cells in Mesothelin Expressing Cancers
- Conditions: Mesothelioma, Mesothelioma, Malignant, Fallopian Tube Neoplasms, Adenocarcinoma of Lung
- Last Updated: March 10, 2022
- Status: Recruiting
- Location: Philadelphia, PA.
- Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
- Conditions: Carcinoma, Merkel Cell, Lymphoma, Carcinoma, Endometrial Neoplasms, Mesothelioma, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell
- Last Updated: March 4, 2022
- Status: Recruiting
- A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
- Conditions: Mesothelioma
- Last Updated: March 2, 2022
- Status: Recruiting
- Location: Chicago, Illinois.
- Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung
- Conditions: Lung Cancer Adenocarcinoma, Lung Cancer Squamous Cell|, Mesothelioma
- Last Updated: February 8, 2022
- Status: Recruiting
- Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
- Conditions: Carcinoma, Carcinoma, Renal Cell, Endometrial Neoplasms, Mesothelioma, Carcinoma, Non-Small-Cell Lung
- Last Updated: January 31, 2022
- Status: Recruiting
- A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: January 28, 2022
- Status: Recruiting
- Locations: Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. Uniondale, NY.
- eRAPID: Online Symptom Reporting in Lung Cancer
- Conditions: Lung Neoplasms, Small Cell Lung Carcinoma, Mesothelioma
- Last Updated: January 27, 2022
- Status: Recruiting
- A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma
- Conditions: Lung Neoplasms, Mesothelioma, Mesothelioma, Malignant
- Last Updated: January 26, 2022
- Status: Recruiting
- Locations: Cleveland, OH. Philadelphia, PA. Nashville, TN.
- Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis
- Conditions: Mesothelioma, Carcinoma, Peritoneal Neoplasms, Pseudomyxoma Peritonei
- Last Updated: January 24, 2022
- Status: Recruiting
- Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma
- Conditions: Malignant Peritoneal Mesothelioma
- Last Updated: January 14, 2022
- Status: Recruiting
- Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms
- Last Updated: January 5, 2022
- Status: Recruiting
- Location: Houston, TX.
- Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
- Conditions: Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma, SCLC, Mesothelioma, Neuroendocrine Tumors, Colorectal Neoplasms, Endometrial Carcinoma, Carcinoma, Ovarian Epithelial, Pancreatic Adenocarcinoma
- Last Updated: December 2, 2021
- Status: Recruiting
- Locations: Boston, MA. Boston, MA.
- A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat
- Conditions: Lymphoma, Neoplasms, Sarcoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Mesothelioma, Hematologic Neoplasms, Rhabdoid Tumor, Sarcoma, Synovial, Carcinoma, Medullary
- Last Updated: December 15, 2021
- Status: Recruiting
- Locations: Encinitas, CA. Los Angeles, CA. Chicago, IL. Grand Rapids, MI. Canton, OH. Cincinnati, OH. Dallas, TX.
- Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: December 9, 2021
- Status: Recruiting
- Locations: Tampa, FL. Boston, MA. Rochester, MN. Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. Rockville Centre, NY. Sleepy Hollow, NY. Uniondale, NY. Houston, TX.
- Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant, Wilms Tumor
- Last Updated: December 8, 2021
- Status: Recruiting
- Locations: Basking Ridge, NJ. Middletown, NJ. Commack, NY. Harrison, NY. New York, NY. Uniondale, NY.
- Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: December 2, 2021
- Status: Recruiting
- Locations: Birmingham, AL. Phoenix, AZ. Scottsdale, AZ. Duarte, CA. La Jolla, CA. Los Angeles, CA. Los Angeles, CA. Newport Beach, CA. Aurora, CO. Aventura, FL. Coral Gables, FL. Deerfield Beach, FL. Jacksonville, FL. Miami, FL. Miami, FL. Plantation, FL. Chicago, IL. Chicago, IL. Lexington, KY. Baltimore, MD. Baltimore, MD. Boston, MA. Boston, MA. Rochester, MN. Creve Coeur, MO. Saint Louis, MO. Saint Louis, MO. Saint Peters, MO. Durham, NC. Pittsburgh, PA. Dallas, TX. Salt Lake City, UT.
- Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: December 2, 2021
- Status: Recruiting
- Location: Rochester, MN.
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: November 6, 2021
- Status: Recruiting
- Locations: Boston, MA. Rochester, MN.
- Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)
- Conditions: Mesothelioma, Mesothelioma, Malignant, Carcinoma, Peritoneal Neoplasms
- Last Updated: November 4, 2021
- Status: Recruiting
- Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations
- Conditions: Mesothelioma
- Last Updated: November 2, 2021
- Status: Recruiting
- Locations: Chicago, Illinois. Boston, Massachusetts. Houston, Texas. San Antonio, Texas.
- Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
- Conditions: Mesothelioma, Carcinoma, Peritoneal Neoplasms, Pseudomyxoma Peritonei, Hyperthermia, Fever
- Last Updated: October 15, 2021
- Status: Recruiting
- UNITO-001-A Phase II Study in HRR/PDL1 Positive MPM/NSCLC
- Conditions: Mesothelioma
- Last Updated: October 14, 2021
- Status: Recruiting
- A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: October 4, 2021
- Status: Recruiting
- Short Neoadjuvant Hemithoracic IMRT for MPM
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: October 4, 2021
- Status: Recruiting
- Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
- Conditions: Carcinoma, Breast Neoplasms, Carcinoma, Squamous Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms, Mesothelioma, Squamous Cell Carcinoma of Head and Neck
- Last Updated: October 3, 2021
- Status: Recruiting
- PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis
- Conditions: Carcinoma, Peritoneal Neoplasms
- Last Updated: September 21, 2021
- Status: Recruiting
- Dose Individualization of Pemetrexed – IMPROVE-II
- Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant
- Last Updated: September 14, 2021
- Status: Recruiting
- Dose Individualization of Pemetrexed – IMPROVE-III
- Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant
- Last Updated: September 14, 2021
- Status: Recruiting
- Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
- Conditions: Neoplasms, Peritoneal Neoplasms
- Last Updated: September 13, 2021
- Status: Recruiting
- Location: Boston, MA.
- Real World Study of MPM in China
- Conditions: Mesothelioma, Mesothelioma, Malignant Pleural
- Last Updated: September 13, 2021
- Status: Recruiting
- Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
- Conditions: None
- Last Updated: September 13, 2021
- Status: Recruiting
- Location: Boston, MA.
- A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: September 5, 2021
- Status: Recruiting
- Location: Ventura, CA.
- Cardiac MRI Biomarker Testing (GCC 1618)
- Conditions: Mesothelioma, Thymus Neoplasms
- Last Updated: August 16, 2021
- Status: Recruiting
- Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
- Conditions: Carcinoma, Breast Neoplasms, Melanoma, Carcinoma, Squamous Cell, Adenocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Mesothelioma, Cholangiocarcinoma, Squamous Cell Carcinoma of Head and Neck, Endometrial Neoplasms, Adenocarcinoma of Lung, Thyroid Neoplasms, Esophageal Neoplasms, Cystadenocarcinoma, Carcinosarcoma, Urinary Bladder Neoplasms, Adenomyoepithelioma, Adenocarcinoma, Clear Cell, Cystadenocarcinoma, Serous
- Last Updated: August 13, 2021
- Status: Recruiting
- Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: August 9, 2021
- Status: Recruiting
- Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
- Conditions: Uterine Cervical Neoplasms, Mesothelioma, Carcinoma, Non-Small-Cell Lung, Thymoma, Thymus Neoplasms
- Last Updated: July 31, 2021
- Status: Recruiting
- SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
- Conditions: Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant
- Last Updated: July 23, 2021
- Status: Recruiting
- Phase II Nivolumab and Ramucirumab for Previously-Treated Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: July 21, 2021
- Status: Recruiting
- Locations: Tampa, FL. Baltimore, MD. Detroit, MI. Minneapolis, MN.
- Peritoneal Surface Malignancies – Characterization, Models, and Treatment Strategies
- Conditions: Pseudomyxoma Peritonei, Colorectal Carcinoma, Mesothelioma, Ovarian Carcinoma, Peritoneal Neoplasms
- Last Updated: July 21, 2021
- Status: Recruiting
- Mesothelin-targeted CAR T-cell Therapy for Mesothelioma Patients
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: July 19, 2021
- Status: Recruiting
- Pilot Window-Of-Opportunity Study of Anti-PD-1 Antibody Pembrolizumab in Resectable Malignant Pleural Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: June 30, 2021
- Status: Recruiting
- Location: Chicago, IL.
- The IMmunotherapy Pleural 5-ALA PDT
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: May 18, 2021
- Status: Recruiting
- Olaparib in HRD Malignant Mesothelioma Patients
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: May 12, 2021
- Status: Recruiting
- Location: Chicago, IL.
- Tissue Procurement for Various Cancers in Patients Undergoing Surgery or Biopsy
- Conditions: Stomach Neoplasms, Esophageal Neoplasms, Mesothelioma, Gastrointestinal Stromal Tumors, Anus Neoplasms, Pancreatic Neoplasms, Liver Neoplasms, Carcinoma, Hepatocellular, Gastrointestinal Neoplasms
- Last Updated: May 12, 2021
- Status: Recruiting
- BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: April 30, 2021
- Status: Recruiting
- Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Advanced Tumours
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: April 30, 2021
- Status: Recruiting
- Locations: Various
- Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
- Conditions: Carcinoma, Melanoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Mesothelioma, Mesothelioma, Malignant, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Breast Neoplasms, Lung Neoplasms, Carcinoma, Basal Cell, Squamous Cell Carcinoma of Head and Neck, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Neuroendocrine, Thymoma, Small Cell Lung Carcinoma, Anus Neoplasms, Vulvar Neoplasms
- Last Updated: April 28, 2021
- Status: Recruiting
- Locations: Various
- Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
- Conditions: Carcinoma, Merkel Cell, Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Squamous Cell, Ovarian Neoplasms, Carcinoma, Hepatocellular, Stomach Neoplasms, Uterine Cervical Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Mesothelioma, Mesothelioma, Malignant, Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Anus Neoplasms, Thymus Neoplasms, Microsatellite Instability
- Last Updated: April 15, 2021
- Status: Recruiting
- Locations: New Haven, CT. Houston, TX.
- Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: April 12, 2021
- Status: Recruiting
- Oral TrkA Inhibitor VMD-928 for Advanced Adult Solid Tumors or Lymphoma
- Conditions: Lymphoma, Carcinoma, Prostatic Neoplasms, Leukemia, Myeloid, Melanoma, Carcinoma, Squamous Cell, Leukemia, Myeloid, Acute, Ovarian Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Stomach Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Mesothelioma, Malignant, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Adenoid Cystic, Thymoma, Lung Neoplasms
- Last Updated: March 11, 2021
- Status: Recruiting
- Locations: Various
- Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
- Conditions: Neoplasm Metastasis, Brain Neoplasms, Astrocytoma, Mesothelioma, Cholangiocarcinoma, Esophageal Neoplasms, Tongue Neoplasms, Thymoma, Urologic Neoplasms
- Last Updated: March 8, 2021
- Status: Recruiting
- Pleurectomy/Decortication (P/D) Preceded or Followed by Chemotherapy in Early Stage MPM
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: March 5, 2021
- Status: Recruiting
- Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural Mesothelioma Patients
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: March 2, 2021
- Status: Recruiting
- Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: February 26, 2021
- Status: Recruiting
- Pembrolizumab Plus Autologous Dendritic Cell Vaccine in PD-L1 Negative Advanced Mesothelioma Patients
- Conditions: Mesothelioma, Mesothelioma, Malignant, Disease Progression
- Last Updated: February 26, 2021
- Status: Recruiting
- Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: February 25, 2021
- Status: Recruiting
- DENdritic Cell Immunotherapy for Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: January 27, 2021
- Status: Recruiting
- Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
- Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant
- Last Updated: January 22, 2021
- Status: Recruiting
- Autologous Dendritic Cell Vaccination in Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: January 19, 2021
- Status: Recruiting
- Rehabilitation by Effort for Advanced Bronchial Cancer Patients
- Conditions: Mesothelioma, Mesothelioma, Malignant, Carcinoma, Bronchogenic
- Last Updated: July 29, 2020
- Status: Recruiting
- αPD1-MSLN-CAR T Cells for Treating MSLN-positive Advanced Solid Tumors
- Conditions: Mesothelioma
- Last Updated: July 28, 2020
- Status: Recruiting
- Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant, Hyperthermia
- Last Updated: July 14, 2020
- Status: Recruiting
- HMPL-453 in Advanced Malignant Mesothelioma
- Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms
- Last Updated: June 16, 2020
- Status: Recruiting
- 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumors
- Conditions: Mesothelioma, Neuroendocrine Tumors, Thymoma
- Last Updated: May 5, 2020
- Status: Recruiting
- Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed
- Conditions: Mesothelioma
- Last Updated: December 13, 2019
- Status: Recruiting
- Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
- Conditions: Leukemia, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Mesothelioma, Sarcoma, Synovial, Esophageal Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms
- Last Updated: December 11, 2019
- Status: Recruiting
- Mesothelioma and Radical Surgery 2
- Conditions: Mesothelioma, Mesothelioma, Malignant
- Last Updated: October 28, 2019
- Status: Recruiting
- International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
- Conditions: Mesothelioma, Pancreatic Neoplasms, Gallbladder Neoplasms, Pseudomyxoma Peritonei, Appendiceal Neoplasms, Pleural Effusion, Ascites
- Last Updated: October 7, 2019
- Status: Recruiting
- uPAR-PET for Prognostication in Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma, and Large Cell Neuroendocrine Carcinoma of the Lung
- Conditions: Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant, Carcinoma, Neuroendocrine
- Last Updated: November 21, 2016
- Status: Recruiting